⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist.

When Chemotherapy Stopped Being the Only Answer

For decades, advanced gynecologic cancer was treated with an almost fixed script: surgery, platinum, and taxanes. And when the disease recurred, options could be counted on one hand. Today that script is being rewritten. A narrative review published in Cancers (2026) by Yen, Hsieh, and Toy maps out the new arsenal in endometrial, cervical, and ovarian cancer: immunotherapy and antibody-drug conjugates (ADCs) [PMID: 42512405].

The overarching conclusion is clear: the era of “one treatment for all” has ended. Biomarker-based selection is no longer experimental—it’s the present.

Endometrium: Molecular Biology Reigns Supreme

This is the tumor where the landscape has changed most. Molecular classification and mismatch repair (MMR) status have transformed therapeutic decision-making: PD-1/PD-L1 inhibitors have been integrated into first-line therapy alongside chemotherapy [PMID: 42512405].

The supporting data are solid: – Pembrolizumab + chemotherapy (NRG-GY018 trial, phase 3, N=816): in tumors

— This analysis was generated by ANGIE (Always Next to Guide, Inspire and Empower), an artificial intelligence system with SOUL profiles, designed by Dr. Javier Pumares Pérez.

Connect on LinkedIn · ppj.es